Allogene Therapeutics (ALLO) Amortizatization of Intangibles (2018 - 2026)

Allogene Therapeutics recorded quarterly Amortizatization of Intangibles of $885000.0 in Q1 2026, up 7.8% quarter-over-quarter from $821000.0 in Q4 2025, and down 32.24% year-over-year from $1.3 million in Q1 2025.

Allogene Therapeutics' Amortizatization of Intangibles history runs 9 years deep, the most recent figure standing at $885000.0 for Q1 2026.

  • In Q1 2026, Amortizatization of Intangibles fell 32.24% year-over-year to $885000.0; the TTM figure through Mar 2026 stood at $3.8 million (down 44.58% YoY), while the FY2025 annual figure was $4.2 million, down 49.44% from the prior year.
  • Amortizatization of Intangibles came in at $885000.0 for Q1 2026 at Allogene Therapeutics, up from $821000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $3.3 million in Q4 2023 to a low of -$1.3 million in Q1 2022.
  • A 5-year average of $1.0 million and a median of $1.1 million in 2023 frame the typical range for Amortizatization of Intangibles.
  • Across the five-year window, Amortizatization of Intangibles soared 2214.74% in 2023 and plunged 53.31% in 2025, its largest moves.
  • Allogene Therapeutics' Amortizatization of Intangibles stood at -$156000.0 in 2022, then jumped by 2214.74% to $3.3 million in 2023, then plunged by 49.95% to $1.7 million in 2024, then plunged by 50.27% to $821000.0 in 2025, then grew by 7.8% to $885000.0 in 2026.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $885000.0, $821000.0, and $923000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 13,267.00
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Allogene Therapeutics 521.43 Mn 521.43 Mn - 885,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 885,000.00
Mar 31, 2026 885,000.00
Dec 31, 2025 821,000.00
Dec 31, 2025 821,000.00
Sep 30, 2025 923,000.00
Sep 30, 2025 923,000.00
Jun 30, 2025 1.17 Mn
Jun 30, 2025 1.17 Mn
Mar 31, 2025 1.31 Mn
Mar 31, 2025 1.31 Mn
Dec 31, 2024 1.65 Mn
Dec 31, 2024 1.65 Mn
Sep 30, 2024 1.70 Mn
Sep 30, 2024 1.70 Mn
Jun 30, 2024 2.20 Mn
Jun 30, 2024 2.20 Mn
Mar 31, 2024 2.80 Mn
Mar 31, 2024 2.80 Mn
Dec 31, 2023 3.30 Mn
Dec 31, 2023 3.30 Mn
Sep 30, 2023 2.94 Mn
Sep 30, 2023 2.94 Mn
Jun 30, 2023 1.07 Mn
Jun 30, 2023 1.07 Mn
Mar 31, 2023 -508,000.00
Mar 31, 2023 -508,000.00
Dec 31, 2022 -156,000.00
Dec 31, 2022 -156,000.00
Sep 30, 2022 -495,000.00
Sep 30, 2022 -495,000.00
Jun 30, 2022 -908,000.00
Jun 30, 2022 -908,000.00
Mar 31, 2022 -1.33 Mn
Mar 31, 2022 -1.33 Mn
Dec 31, 2021 -1.59 Mn
Dec 31, 2021 -1.59 Mn
Sep 30, 2021 -1.62 Mn
Sep 30, 2021 -1.62 Mn
Jun 30, 2021 -1.84 Mn
Jun 30, 2021 -1.84 Mn
Mar 31, 2021 -1.91 Mn
Mar 31, 2021 -1.91 Mn
Dec 31, 2020 1.59 Mn
Dec 31, 2020 1.59 Mn
Sep 30, 2020 -1.59 Mn
Sep 30, 2020 -1.59 Mn
Jun 30, 2020 -56,000.00
Jun 30, 2020 -56,000.00
Mar 31, 2020 207,000.00
Mar 31, 2020 207,000.00
Dec 31, 2019 151,000.00
Dec 31, 2019 151,000.00
Sep 30, 2019 151,000.00
Sep 30, 2019 151,000.00
Jun 30, 2019 -922,000.00
Jun 30, 2019 -922,000.00
Mar 31, 2019 1.22 Mn
Mar 31, 2019 1.22 Mn
Dec 31, 2018 150,000.00
Dec 31, 2018 150,000.00
Sep 30, 2018 200,000.00
Sep 30, 2018 200,000.00